Surrozen, Inc. (SRZN)
NASDAQ: SRZN · Real-Time Price · USD
10.38
-0.17 (-1.61%)
Nov 6, 2024, 4:00 PM EST - Market closed
Surrozen Employees
Surrozen had 42 employees as of December 31, 2023. The number of employees decreased by 32 or -43.24% compared to the previous year.
Employees
42
Change (1Y)
-32
Growth (1Y)
-43.24%
Revenue / Employee
$238,095
Profits / Employee
-$1,058,048
Market Cap
33.28M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 42 | -32 | -43.24% |
Dec 31, 2022 | 74 | -9 | -10.84% |
Dec 31, 2021 | 83 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Nortech Systems | 775 |
KALA BIO | 43 |
AN2 Therapeutics | 41 |
Elevation Oncology | 29 |
Daré Bioscience | 26 |
Lipocine | 17 |
AEON Biopharma | 10 |
Marker Therapeutics | 8 |
SRZN News
- 16 hours ago - Surrozen to Present at Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 1 day ago - Surrozen Provides Third Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 3 days ago - Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 6 weeks ago - Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration - GlobeNewsWire
- 3 months ago - Surrozen Provides Second Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 5 months ago - Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling - GlobeNewsWire
- 5 months ago - Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan - GlobeNewsWire
- 5 months ago - Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis - GlobeNewsWire